The fact that Assembly Biosciences Inc. and AgeneBio now list New York and Baltimore, respectively, as their headquarters cities doesn’t hurt Indiana and could help the state, says David Johnson, CEO of BioCrossroads.
Indiana’s health care companies attracted $103.8 million in investments last year, the highest total since attracting 2007. However, all but $3 million of last year’s investments came during the first six months of the year and Indiana continued to lag other Midwest states.
On Obamacare, the new Republican-controlled Congress should “leave the façade of the building and then demolish the inside of it,” according to one GOP leader. If Republicans take that approach, here are four things that could change in the next two years.
Lilly CEO John Lechleiter kicked off the company’s quarterly conference call with investors and analysts by declaring an end to the “unprecedented challenge” that Lilly lived through the past four years.
In spite of the beaucoup bucks in the pharma sector, patients, along with their families and committed advocates, are turning out to be better sources of funding for early stage companies because they tolerate risk better than drug companies and investors.
With federal research funding declining, drug companies are taking a larger role funding the medical research happening at IU and universities around the country. That's not the same thing as paying to market drugs, but it's hardly without controversy.